fingolimod hydrochloride: clinical use

Prescribing considerations

• Initiation and supervision require a clinician experienced in multiple sclerosis.
• Review cardiac history, ECG, blood pressure and concurrent heart-rate-lowering or QT-prolonging medicines before initiation.
• Check infection history, varicella immunity and vaccination status; delay initiation during severe active infection.
• Assess previous disease-modifying and immunosuppressive therapies to minimise overlapping immune effects.
• Exclude pregnancy where relevant, counsel about foetal risk and confirm effective contraception.
• Plan withdrawal carefully because severe disease reactivation has occurred after discontinuation.

Contraindications and cautions

• Immunodeficiency or increased susceptibility to opportunistic infection, including significant treatment-related immunocompromise
• Suspected or confirmed progressive multifocal leukoencephalopathy
• Severe active or active chronic infection, including hepatitis or tuberculosis
• Active malignancy
• Severe hepatic impairment
• Specified recent cardiovascular or cerebrovascular events and severe heart failure
• Specified conduction disorders without a pacemaker, severe arrhythmias requiring class Ia or III antiarrhythmics, or markedly prolonged baseline QTc
• Pregnancy or childbearing potential without effective contraception
• Hypersensitivity to the active substance or product excipients

Monitoring

• ECG, heart rate and blood pressure around treatment initiation and qualifying restarts; extend observation when clinically indicated.
• Full blood count and lymphocyte count before and periodically during treatment, and when infection is suspected.
• Liver transaminases and bilirubin before, during and after treatment; investigate symptoms of hepatic dysfunction promptly.
• Baseline MRI for reference and ongoing vigilance for clinical or radiological signs of PML.
• Eye assessment after initiation and promptly for visual symptoms; assess higher-risk patients before treatment.
• Regular blood-pressure checks and skin examinations; advise sun protection and review suspicious lesions.
• Monitor for infections during treatment and after discontinuation, and for rebound disease activity after stopping.

Clinical pharmacology

Fingolimod is phosphorylated to an active metabolite that functionally antagonises sphingosine-1-phosphate receptor signalling on lymphocytes. It reversibly redistributes lymphocytes into lymphoid tissue, reducing CNS entry; its receptor effects also explain transient bradycardia and atrioventricular conduction slowing at initiation.

Formulation and product differences

• The selected products are oral hard-capsule formulations containing fingolimod as the hydrochloride salt.
• Capsule appearance, excipients, packaging and storage requirements are product-specific; verify the dispensed product's SmPC and leaflet.
• Fingolimod Olpha capsules have a yellow cap and white opaque body and should be swallowed intact.

Capsule

Route: Oral

Strengths: 0.25 mg, 0.5 mg